SAGIMET BIOSCIENCES INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.62 USD | +5.48% |
|
+4.05% | -14.76% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 124.1 | 147.4 | - | - |
| Enterprise Value (EV) 1 | 124.1 | 6.305 | 5.339 | 59.42 |
| P/E ratio | -2.04 x | -2.25 x | -1.19 x | -0.86 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 62 x | - | - | - |
| EV / Revenue | 62 x | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 22,896 | 31,914 | - | - |
| Reference price 2 | 5.420 | 4.620 | 4.620 | 4.620 |
| Announcement Date | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 2 | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -30.74 | -59.25 | -143.5 | -209.5 |
| Operating Margin | - | -1,537% | - | - | - |
| Earnings before Tax (EBT) 1 | - | -27.88 | -61.05 | -119.1 | -186.7 |
| Net income 1 | -30.5 | -27.88 | -61.05 | -120.1 | -187 |
| Net margin | - | -1,393.8% | - | - | - |
| EPS 2 | -165.3 | -2.660 | -2.055 | -3.892 | -5.360 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/24/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 2 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.057 | -7.452 | -9.466 | -8.768 | -10.97 | -14.45 | -21.8 | -27.19 | -29.38 |
| Operating Margin | - | -372.6% | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.785 | -6.353 | -8.151 | -6.629 | -11.49 | -16.52 | -26.42 | -27.19 | -29.38 |
| Net income 1 | -6.785 | -6.353 | -8.151 | -6.629 | -11.49 | -16.52 | -26.42 | -27.19 | -29.38 |
| Net margin | - | -317.65% | - | - | - | - | - | - | - |
| EPS 2 | -35.80 | -0.3500 | - | -0.2300 | -0.3850 | -0.5500 | -0.8800 | -0.9300 | -1.000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/21/23 | 11/13/23 | 3/25/24 | 5/15/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 141 | 142 | 88 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/24/23 | 3/25/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.62
USD
Average target price
39.2
USD
Spread / Average Target
+748.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.76% | 147M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- SGMT Stock
- Financials Sagimet Biosciences Inc.
